# EDGAR Filing Document

**Accession Number:** 0001553643
**File Stem:** 0001213900-26-040821
**Filing Date:** 2026-4
**Character Count:** 2389
**Document Hash:** 706e9e8bfa9674d6c67fbcbcd7e36e33
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-040821.hdr.sgml**: 20260507

**ACCESSION NUMBER**: 0001213900-26-040821

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260407

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** RELMADA THERAPEUTICS, INC.
- **CENTRAL INDEX KEY:** 0001553643
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 455401931
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 2222 PONCE DE LEON BLVD. 3RD FLOOR
- **CITY:** CORAL GABLES
- **STATE:** FL
- **ZIP:** 33134
- **BUSINESS PHONE:** 646 876 3459

**MAIL ADDRESS:**
- **STREET 1:** 2222 PONCE DE LEON BLVD. 3RD FLOOR
- **CITY:** CORAL GABLES
- **STATE:** FL
- **ZIP:** 33134

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CAMP NINE, INC.
- **DATE OF NAME CHANGE:** 20120706

April 7, 2026

 

*VIA EDGAR* 

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

---

| | |
|:---|:---|
| **Re:** | **Relmada Therapeutics, Inc.** |
|  | **Registration Statement on Form S-3** |
|  | **File No. 333-294885** |

---

---

| | |
|:---|:---|
| **Acceleration Request** | **Acceleration Request** |
| **Requested Date:** | **April 9, 2026** |
| **Requested Time:** | **4:05 p.m.**, **Eastern Time** |

---

Dear Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Relmada Therapeutics, Inc. (the "Company") hereby requests that the above-referenced Registration Statement (the "Registration Statement") be declared effective by the Securities and Exchange Commission (the "Commission") at the "Requested Date" and "Requested Time" set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Commission.

Please call Tracy Buffer of Lowenstein Sandler LLP at (973) 597-2434 to confirm the effectiveness of the Registration Statement or with any questions.

---

| | |
|:---|:---|
| Sincerely, | Sincerely, |
| RELMADA THERAPEUTICS, INC. | RELMADA THERAPEUTICS, INC. |
| By: | */s/ Sergio Traversa* |
| Name: | Sergio Traversa |
| Title: | Chief Executive Officer |

---